<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002463</url>
  </required_header>
  <id_info>
    <org_study_id>P88-006</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-P-88006</secondary_id>
    <secondary_id>NCI-V89-0125</secondary_id>
    <secondary_id>CDR0000075917</secondary_id>
    <nct_id>NCT00002463</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors</brief_title>
  <official_title>Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine,&#xD;
      vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive&#xD;
      neuroectodermal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of high-dose methotrexate (HMTX) in combination with&#xD;
      mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) in infants or young&#xD;
      children with primitive neuroectodermal tumors (PNET) (including medulloblastoma, anaplastic&#xD;
      ependymoma, ependymoblastoma, or pineoblastoma) or high-grade astrocytoma. II. Determine&#xD;
      whether the addition of HMTX to MOPP (MMOPP) improves the continuous complete response rate&#xD;
      of MOPP alone and eliminates the need for salvage with radiotherapy in these patients. III.&#xD;
      Determine the ability of MMOPP to provide neuroaxis prophylaxis or to treat spinal metastasis&#xD;
      without radiotherapy in infants or young children with PNET. IV. Determine the toxicity of&#xD;
      this regimen in terms of neurologic and neuropsychologic sequelae, growth, and development in&#xD;
      these patients. V. Correlate the efficacy of this regimen with the histopathologic diagnosis&#xD;
      of these patients. VI. Determine the optimum method for radiographic evaluation of spinal&#xD;
      cord disease in patients with PNET. VII. Determine the utility of sequential spinal cord&#xD;
      radiography as a means of monitoring PNET in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo maximum tumor debulking. Patients who have undergone incomplete&#xD;
      resection proceed to induction. Patients with a primary diagnosis of primitive&#xD;
      neuroectodermal and pineal tumors or glioblastoma multiforme who have undergone total&#xD;
      resection proceed to induction. Induction: Patients receive high dose methotrexate (HMTX) IV&#xD;
      over 6 hours on day 1. Beginning 3 hours after completion of HMTX infusion, leucovorin&#xD;
      calcium (CF) is administered IV over 30 minutes every 3 hours for 9 doses. Beginning 3 hours&#xD;
      after completion of the last CF infusion, oral CF is administered every 6 hours for 8 doses.&#xD;
      Patients receive a second HMTX infusion beginning 1 week after completion of the first HMTX&#xD;
      infusion. Beginning 1 week after completion of the second HMTX infusion, patients receive&#xD;
      mechlorethamine IV and vincristine IV on days 1 and 8, oral procarbazine and oral prednisone&#xD;
      on days 1-10, and tapered doses of prednisone on days 11-13 (MOPP). Maintenance: Beginning 4&#xD;
      weeks after initiating the first course of MOPP, patients receive HMTX on day 1 and MOPP&#xD;
      beginning on day 4. Treatment continues every 31 days in the absence of disease progression&#xD;
      or unacceptable toxicity. After 1 year or 14 doses of HMTX, whichever occurs first, HMTX is&#xD;
      discontinued and treatment with MOPP alone continues every 4 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity. Treatment is discontinued after 2 years if the patient&#xD;
      is in continuous complete remission.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study within 24-30&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1989</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patient with Overall Response</measure>
    <time_frame>Every 31 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOPP Regimen</intervention_name>
    <description>Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)</description>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mechlorethamine Hydrochloride</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine Hydrochloride</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven previously untreated (except surgically)&#xD;
        primitive neuroectodermal tumors (including medulloblastoma, anaplastic ependymoma,&#xD;
        ependymoblastoma, or pineoblastoma) or high-grade astrocytomas Low-grade astrocytomas or&#xD;
        optic tract tumors that are incompletely resected and have a progressive course not&#xD;
        amenable to further surgery may also be allowed Evaluable disease by MRI, CT scan, or CT&#xD;
        myelography&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Under 4 years Performance status: Not specified Life&#xD;
        expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than&#xD;
        1,500/mm3 WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic:&#xD;
        Bilirubin less than 1.5 mg/dL SGPT less than 90 IU/dL Renal: Creatinine clearance greater&#xD;
        than 80 mL/min&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No&#xD;
        prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) No prior high-dose&#xD;
        methotrexate No other concurrent chemotherapy Endocrine therapy: Not specified&#xD;
        Radiotherapy: No concurrent radiotherapy Surgery: See Disease Characteristics Other:&#xD;
        Recovered from acute toxic effects of any prior therapy Must be on a tyramine-free diet&#xD;
        during procarbazine administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joann Ater, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ater J, Worth L, Bruner J, et al.: Young children treated with MOPP or methotrexate-MOP for medulloblastoma: identification of a subset of patients with good prognosis. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1397, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Ater JL, van Eys J, Yung WK, et al.: Response to methotrexate, mechlorethamine, vincristine, procarbazine, and prednizone (MMOPP) for brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 10: A-370, 125, 1991.</citation>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebellar astrocytoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

